Drug Search Results
More Filters [+]

Perzinfotel

Alternative Names: perzinfotel, eaa-090, eaa090, eaa 090
Latest Update: 2013-02-21
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: GLUN Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Perzinfotel

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peripheral Nervous System Diseases|Neuralgia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

0912A2-212

P2

Terminated

Neuralgia|Peripheral Nervous System Diseases

2004-12-01

Recent News Events

Date

Type

Title